Anesiva and Transcription Factor Therapeutics : Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program

June 5, 2008 - Anesiva, Inc. (Nasdaq: ANSV) announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics, Inc. (TFT). NF-kB Transcription Factor Decoy inhibits NF-kappa B, a protein implicated in the inflammatory cascade in diseases such as inflammatory bowel disease (IBD), eczema, rheumatoid arthritis, and asthma... Anesiva's Press Release -